Abstract:
The present invention relates to the use of a gonadotropin-releasing hormone (including GnRH I, a GnRH I analogue, GnRH II, or a GnRH II analogue) as adjuvant immunotherapeutic.
Abstract:
The present disclosure is directed to methods of treating cancer comprising administering dihydrotestosterone, a dihydrotestosterone derivative, a dihydrotestosterone promoter, or a combination thereof to a patient in need of treatment.
Abstract:
The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
Abstract:
Trata-se de uma formulação farmacêutica nasal de testosterona e um conjunto de dispositivos, constituindo um kit farmacêutico em forma de cartela, destinado a administração de testosterona por via nasal, formado de pluralidade de dispositivos de aplicação de uma única dose-monodose, terapeuticamente medida. O conjunto de dispositivos que se constitui no kit farmacêutico caracteriza-se por um conjunto de dispositivos individuais (1) contendo formulação em gel a base de testosterona micronizada, de alta viscosidade, em baixa dosagem do hormônio, de modo a prover a um paciente, seja do sexo feminino ou masculino doses unitárias, precisamente medidas e fisiologicamente adequadas, de testosterona. O dispositivo após seu uso é imediatamente descartado pelo usuário, sem que haja perdas residuais do hormônio mesmo na administração pela via nasal, em face da alta viscosidade da formulação que aliada ao sistema de bombeamento de ar, do medicamento contido no dispositivo, assegura a liberação de praticamente todo o seu conteúdo. Cada dispositivo é dotado de câmara oca (2), onde se acondiciona o medicamento, e área de coluna de ar que atua como um êmbolo para a expulsão do volume de medicamento contido na câmara (2). Câmara de ar de expulsão (3) fornece ar pressionado pelo usuário ao interior da câmara oca (2), o qual atua como ar comprimido em face de passar, pressionado, pelo pescoço (6) provido entre a câmara oca (2) e a câmara de ar (3). Linhas de rasgamento (8 – 9 – 12) são previstas para facilitar a retirada de cada dispositivo da cartela, para a sua utilização.
Abstract:
Liquid polymer pharmaceutical compositions with a biodegradable liquid polyester that has a carboxylic acid end group, a biocompatible solvent, and an active pharmaceutical agent are useful for administration into the body to provide extended long term release of the drug.
Abstract:
H:\dar\Interwoven\NRPortbl\DCC\DAR\8230712_1.doc-12/08/2015 Abstract The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
Abstract translation:H:\ dar \ Interwoven \ NRPortbl \ DCC \ DAR \ 8230712_1.doc-12/08/2015摘要本发明涉及化合物及其用途,特别是促进药剂转运至前体药物形式的化合物 淋巴系统并随后增强母体药物的释放。
Abstract:
An applicator for applying a fluid to a surface is provided, the applicator comprising a support comprising an upper outer surface and a lower holding surface; a flexible membrane comprising a central opening, an inner wall comprising a lower end and an upper end, an outer wall at least partially surrounding the upper outer surface of the support, the outer wall comprising a lower end and an upper end, and an upper folded wall connecting the upper ends of the inner wall and outer wall; and a membrane holder for fixedly securing the lower end of the inner wall of the flexible membrane to the upper outer surface of the support; wherein the upper surface of the membrane holder and the inner wall of the flexible membrane define a reservoir for holding a fluid, and wherein the lower end of the outer wall of the flexible membrane is free to move axially relative to the upper outer surface of the support when pressure is applied to the upper folded wall of the flexible membrane. In an embodiment, the applicator has particular utility for applying a topical or transdermal testosterone composition to the skin of a patient in need of testosterone replacement therapy.
Abstract:
The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.